Clinical Trial

RADA16 for Aquablation Day Case

Study acronym: RAD
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2026 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a pilot proof of concept single-arm study using PuraStat following Aquablation procedure to assess reduction of hematuria to allow for same day discharge. The primary objective is to assess how PuraStat affects post-operative hematuria following Aquablation. The secondary objective is to assess the number of patients discharged on the same day based on the hematuria criteria (Grade 0 and Grade I).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-28.
Trial Details
NCT Number NCT06948331
Lead Sponsor NYU Langone Health
Conditions Hematuria, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Enrollment 25 participants
Start Date 2026-04-01
Primary Completion 2026-07-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-27